Healthcare >> Sector Roundtables >> April 28, 2003
KELLY HOLMAN is a Founder and Managing Director of Genesys Capital and
has extensive commercial and technical experience in the biotechnology
industry. Since co-founding Genesys Capital Partners in 2000, he has
been actively involved in assisting the Triax-Covington NewGen Funds
raise over $100 million of venture capital and has been instrumental in
deploying over $60 million across 16 investments. He serves on the Board
of Directors of Affinium Pharmaceuticals Inc., Epocal Inc., matRegen
Corp. and Interface Biologics Inc. He is active in deal origination and
company creation and has advised Canada's National Biotechnology
Advisory Committee on strategies for financing startup and early-stage
biotechnology companies. He holds a Bachelor of Science (honors) in
Biochemistry and an MBA, both from Queen's University. Profile
CLAUDE CAMIR has had a 20-year career covering the pharmaceutical,
biotech and medical devices industries, including the last four years as
a healthcare analyst. His coverage of the sector includes biotech,
service and manufacturing companies in Canada and the US. He has worked
in senior and managerial positions covering marketing, finance and
business development activities for Abbott Laboratories, Aventis (Rhone-
Poulenc Rorer) and Biochem Pharma. He has been involved extensively in
technology valuation, financing and mergers and acquisitions in North
America and Europe. He has received his B. Comm (Finance/Accounting)
degree from the University of Sherbrooke. He is currently enrolled in
the MBA program at the Universit_ du Qu_bec in Montreal and the CFA
program level 2 (exam scheduled for June 2003). Profile
markets in biotech?
Mr. Holman: From the buyside perspective, there certainly is. It's
really a function of the maturity of
